Efgartigimod PH20 SC
ApprovedActive 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Chronic Inflammatory Demyelinating Polyneuropathy
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Trial Timeline
Dec 10, 2024 → Feb 23, 2026
NCT ID
NCT06637072About Efgartigimod PH20 SC
Efgartigimod PH20 SC is a approved stage product being developed by Argenx for Chronic Inflammatory Demyelinating Polyneuropathy. The current trial status is active. This product is registered under clinical trial identifier NCT06637072. Target conditions include Chronic Inflammatory Demyelinating Polyneuropathy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07264426 | Pre-clinical | Recruiting |
| NCT06909214 | Approved | Recruiting |
| NCT06684847 | Phase 3 | Recruiting |
| NCT06637072 | Approved | Active |
| NCT06392386 | Phase 2/3 | Recruiting |
| NCT05979441 | Phase 3 | Recruiting |
| NCT04812925 | Phase 3 | Active |
| NCT04818671 | Phase 3 | Completed |
| NCT04687072 | Phase 3 | Completed |
| NCT04280718 | Phase 2 | Active |
Competing Products
20 competing products in Chronic Inflammatory Demyelinating Polyneuropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |